Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Open Access
Abstract
The prevalence of obesity continues to grow rapidly worldwide, posing many public health challenges of the 21st century. Obese subjects are at major risk for serious diet-related noncommunicable diseases, including type 2 diabetes mellitus, cardiovascular disease, and non-alcoholic fatty liver disease. Understanding the mechanisms underlying obesity pathogenesis is needed for the development of effective treatment strategies. Dysregulation of incretin secretion and actions has been observed in obesity and related metabolic disorders; therefore, incretin-based therapies have been developed to provide new therapeutic options. Incretin mimetics present glucose-lowering properties, together with a reduction of appetite and food intake, resulting in weight loss. In this review, we describe the physiology of two known incretins—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and their role in obesity and related cardiometabolic disorders. We also focus on the available and incoming incretin-based medications that can be used in the treatment of the above-mentioned conditions.Keywords
This publication has 260 references indexed in Scilit:
- Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studiesDiabetologia, 2013
- Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological PerspectiveJournal of Nutrition and Metabolism, 2012
- Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetesNature Genetics, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 Are Associated with Glucose Metabolism in the ChinesePLOS ONE, 2010
- Association analyses of 249,796 individuals reveal 18 new loci associated with body mass indexNature Genetics, 2010
- Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has A Direct Role in Decreasing Hepatic Steatosis in Vitro by Modulating Elements of the Insulin Signaling PathwayHepatology, 2010
- Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challengeNature Genetics, 2010
- Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric bandingSurgery for Obesity and Related Diseases, 2007
- Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditureJournal of Clinical Investigation, 2007